SCHEMBL4675326

SCHEMBL4675326

O=C(Cc1ccc(Cc2ccccc2Cl)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
PKM P14618 1/20 0.38
NLRP3 Q96P20 2/20 0.35
AR P10275 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
PTGER1 P34995 1/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CASP6 P55212 1/20 0.32
MAPT P10636 1/20 0.32
CFTR P13569 1/20 0.32
GFER P55789 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677055 0.86 AR (0.33) ALDH1A1ARMEN1KMT2ALMNA
SCHEMBL4678598 0.84 AR (0.37) ARPOLBMAPT
SCHEMBL4678503 0.84 AR (0.37) ARPOLBMEN1KMT2ALMNA
SCHEMBL4678966 0.83 PTGER1 (0.35) PTGER1POLBL3MBTL1
SCHEMBL4676468 0.83 AR (0.33) ALDH1A1NLRP3ARPDE3BPDE3A
SCHEMBL4674478 0.83 AR (0.33) ALDH1A1PKMNLRP3ARPDE3B
SCHEMBL4678602 0.82 SMN1; SMN2 (0.38) ALDH1A1PKMPTGER1POLBKMT2A
SCHEMBL4675031 0.82 AR (0.36) ALDH1A1NLRP3ARPDE3BPDE3A
SCHEMBL4672955 0.81 HCAR2 (0.43) ALDH1A1PDE3BPDE3APTGER1MEN1
SCHEMBL4680139 0.81 ALDH1A1 (0.36) ALDH1A1PKMLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885PKM 2609/4885NLRP3 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.